We are live on ! Find out more
PRLD icon

Prelude Therapeutics
PRLD

60 hedge funds and large institutions have $188M invested in Prelude Therapeutics in 2022 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 13 increasing their positions, 24 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 5

31% more capital invested

Capital invested by funds: $144M → $188M (+$44.2M)

13% more funds holding

Funds holding: 53 → 60 (+7)

1.81% less ownership

Funds ownership: 87.35% → 85.54% (-1.8%)

46% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 24

Holders
60
Holders Change
+7
Holders Change %
+13.21%
% of All Funds
0.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
13
Reduced
24
Closed
5
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
-$1.52M

Top Buyers

Rank Fund Capital Flow
1
Barclays
Barclays
United Kingdom
+$549K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$511K
3
CS
Candriam SCA
Luxembourg
+$348K
4
Citigroup
Citigroup
New York
+$330K
5
6CM
683 Capital Management
New York
+$183K

Top Sellers

Rank Fund Capital Flow
1
HA
HHLR Advisors
Cayman Islands
-$3.86M
2
Morgan Stanley
Morgan Stanley
New York
-$563K
3
UBS AM
UBS AM
Illinois
-$427K
4
BlackRock
BlackRock
New York
-$420K
5
Two Sigma Investments
Two Sigma Investments
New York
-$344K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$61.1M – – –
O
2
OrbiMed
New York
$60.6M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$27.7M -$314K -48,955 -1%
UBS AM
4
UBS AM
Illinois
$14.1M -$427K -66,651 -3%
Vanguard Group
5
Vanguard Group
Pennsylvania
$5.43M +$1.72K +269 +0%
Massachusetts Financial Services
6
Massachusetts Financial Services
Massachusetts
$3.11M +$10.8K +1,678 +0.3%
BlackRock
7
BlackRock
New York
$2.38M -$420K -65,581 -14%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$1.82M -$80K -12,488 -4%
CS
9
Candriam SCA
Luxembourg
$1.09M +$348K +54,231 +43%
Bank of America
10
Bank of America
North Carolina
$953K -$61.9K -9,654 -6%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$873K -$53.9K -8,414 -5%
Renaissance Technologies
12
Renaissance Technologies
New York
$824K -$44.2K -6,900 -5%
State of Wisconsin Investment Board
13
State of Wisconsin Investment Board
Wisconsin
$606K -$55.8K -8,700 -8%
Susquehanna International Group
14
Susquehanna International Group
Pennsylvania
$563K +$511K +79,699 +586%
Barclays
15
Barclays
United Kingdom
$549K +$549K +85,656 +1,657%
Morgan Stanley
16
Morgan Stanley
New York
$543K -$563K -87,839 -49%
NYLIM
17
New York Life Investment Management
New York
$495K +$55.2K +8,607 +12%
Two Sigma Advisers
18
Two Sigma Advisers
New York
$455K -$219K -34,233 -31%
D.E. Shaw & Co
19
D.E. Shaw & Co
New York
$411K -$69.7K -10,876 -14%
CANY
20
Caxton Associates (New York)
New York
$395K -$132K -20,539 -24%
Charles Schwab
21
Charles Schwab
California
$385K +$62K +9,669 +18%
Citigroup
22
Citigroup
New York
$363K +$330K +51,540 +604%
Two Sigma Investments
23
Two Sigma Investments
New York
$313K -$344K -53,703 -51%
Millennium Management
24
Millennium Management
New York
$300K -$68.5K -10,690 -18%
GCP
25
GSA Capital Partners
United Kingdom
$289K -$40.8K -6,372 -12%
1
2 3

PRLD Hedge Fund Activity: Q4 2022 in Review

60 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q4 2022, worth a combined $188M — up 31% from $144M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new PRLD positions and 5 closed out — a net gain of 7 holders — while 13 added to existing stakes and 24 trimmed.

The largest buyer was Barclays, adding an estimated $549K. The largest seller was HHLR Advisors, exiting entirely with an estimated $3.86M sold.

  • 60 institutional investors held Prelude Therapeutics (PRLD) as of Q4 2022, up from 53 in Q3 2022.
  • Funds reported $188M of Prelude Therapeutics stock for Q4 2022, up 31% quarter-over-quarter.
  • 12 funds opened new Prelude Therapeutics positions in Q4 2022 and 5 closed out, a net change of +7 holders.
  • The largest Prelude Therapeutics buyer in Q4 2022 was Barclays, an estimated $549K added.
  • The largest Prelude Therapeutics seller in Q4 2022 was HHLR Advisors, an estimated $3.86M sold.

Based on aggregated 13F filings for Q4 2022.